Crossmark

Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors

Crossref DOI link: https://doi.org/10.1038/s41391-023-00706-x

Published Online: 2023-08-24

Published Print: 2024-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gebrael, Georges https://orcid.org/0000-0002-4085-6415
Sayegh, Nicolas https://orcid.org/0000-0003-1924-8148
Thomas, Vinay Mathew

Chigarira, Beverly

Tripathi, Nishita

Jo, Yeon Jung

Li, Haoran

Sahu, Kamal Kant

Srivastava, Ayana

McFarland, Taylor

Maughan, Benjamin L.

Swami, Umang

Agarwal, Neeraj https://orcid.org/0000-0003-1076-0428
License Information

Text and Data Mining valid from 2023-08-24

Version of Record valid from 2023-08-24
More Information

Article History

First Online: 24 August 2023

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below